Clinical Trial Update: Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of GT103 in combination with pembrolizumab for refractory, metastatic non-small cell lung cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• GT103
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Jeffrey Clarke | Conditions: Non Small Cell Lung Cancer, Metastatic NSCLC | Phase 2 | Status: TERMINATED